Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$147.36 USD
+1.09 (0.75%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $144.43 -2.93 (-1.99%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Brokerage Reports
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 21 - 40 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ASND 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
YORVIPATH Approved in Europe as Replacement Therapy;January Launch in Germany
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q3: EU/U.S. TC-PTH Timelines On-Track; SKYTROFA Beat Raise; Pipeline Updates
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-PTH Outlook Unchanged by Slight Adjustment to NDA Resubmission Timeline
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Positive CHMP Opinion for TC-PTH/HP, EU Approval Likely in Nov. 2023
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
U.S. Regulatory Timeline for TC-PTH Becomes Clearer, All Eyes on NDA Acceptance
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Biotechnology - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D